Preimplantation genetic testing for aneuploidy (PGT-A)

PGT-A involves genetically testing embryos prior to transfer into the uterus. PGT-A uses gene-sequencing technologies to identify if embryos have extra or missing DNA (chromosomal aneuploidy). This technique can help identify embryos with abnormal genetics, which can lead to implantation failure, miscarriage, or genetic conditions such as Down syndrome (extra chromosome 21).

As women age, the risk of chromosomal abnormalities increases. This leads to an increased risk of infertility and miscarriage.  PGT-A can help improve the likelihood of a successful pregnancy by identifying the healthiest embryo to transfer.

PGT-A is performed during an in vitro fertilization (IVF) cycle. During IVF, eggs are retrieved from a woman's ovaries and fertilized with sperm in a laboratory. The resulting embryos are then cultured for a few days. A small number of cells are then removed from each embryo and tested for chromosomal abnormalities. The cells biopsied for PGT-A are those destined to be the placenta, not the embryo. In this way, the embryo is not damaged during the biopsy procedure.

PGT-A is often recommended to women with advanced age or couples with recurrent miscarriage. PGT-A can also be used for sex selection in the setting of family balancing.

If you are considering PGT-A, reach out to us today to discuss this in more detail and see if PGT-A is right for you.